Main points of investment
Ophthalmology pharmaceutical company with multiple pipelines: the company is an ophthalmology pharmaceutical company dedicated to the research, development and commercialization of therapies to meet the huge medical needs in China. With deep expertise in the field, the company has established a comprehensive ophthalmic drug pipeline containing 25 drug candidates through independent research and development or licensing, covering most major ophthalmic indications affecting the anterior and posterior segments of the eye. The company was incorporated in January 2017 and is the holding company of Li's Big Pharmaceutical Group. In preparation for the recent product launch, the company has established an advanced ophthalmic manufacturing facility and is setting up an experienced marketing team.
With the huge medical demand and the rapid development of China's ophthalmology market, China's ophthalmology drug market is in its infancy and is growing exponentially with a rapid trend. It is mainly driven by the increasing number of patients with ophthalmic diseases, the increased affordability of patients, and the increase of drugs and treatments. There is a huge gap in the medical demand for ophthalmic drugs in China, which is due to the low diagnosis rate of ophthalmic diseases. China has a large number of patients with eye diseases who have not received adequate treatment at present. According to the prevalence rate of biopharmaceutical market, xerophthalmia, wet age-related macular degeneration, diabetic macular edema, glaucoma, myopia and allergic conjunctivitis are the main eye diseases in China. In 2019, the prevalence of these diseases in China was significantly higher than that in the United States, while the size of China's ophthalmic drug market was only a fraction of that in the United States (about 18%). Dry eyes, wet age-related macular lesions, myopia, diabetic macular edema and glaucoma drugs are expected to be the biggest drivers of the market.
The drug pipeline covers most major ophthalmic indications: the company's R & D team has a proven track record and comprehensive capabilities covering drug discovery, preclinical research and clinical trial execution. The company has a professional preparation team, preparation capacity, and has a good track record in the development of new preparations for innovative drugs. The company also has a mature pharmacological platform through which the company plans to develop animal disease models to test the efficacy of drugs. The company has established ophthalmic product lines for 13 innovative drugs and 12 imitation candidate drug pipelines, covering most major ophthalmic indications. The innovative drug pipeline includes xerophthalmia drug pipeline, wet senile macular disease drug pipeline, diabetic macular edema drug pipeline, myopia drug pipeline, etc., and involves the research and development of cyclosporine An eye gel, RGN-259, cyclosporine A / Ribapet eye gel, IC-265, PAN-90806, TAB014, ZK002, NVK-002 and ZKY001.
Risk tips: excessive expenditure leads to financial pressure, lower-than-expected progress and commercialization of new product research and development, and industry policy risks
